Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Graft Versus Host Disease (GvHD) Treatment Market - Outlook and Forecast 2022-2027
The graft versus host disease (GVHD) treatment market recorded a value of USD 643 million in 2021 and is projected to reach USD 990 million by 2027, exhibiting a compound annual growth rate (CAGR) of 7.44%.
GVHD is a condition that arises when the donor’s immune cells, known as T-cells, attack the recipient patient’s healthy tissues following transplant procedures.
|No. of Pages||
USD 990 Mn incremental growth between 2021 and 2026
Drug Class, Treatment Type, Gender Type, and Geography
|No. of Companies Mentioned||
In terms of the number of hematopoietic stem cell transplants (HSCTs), the United States accounted for the highest figure in 2020, followed by China and Germany. The demand for allo-HSCT (allogeneic HSCT) is experiencing rapid growth, a trend expected to continue in the forecast period. This can be attributed to the increasing incidence of leukemia and lymphoma, improved success rates of transplantation, and a rise in the aging population.
The market is segmented based on various factors, including drug class, treatment type, gender type, and geography.
Segmentation by Drug Class
Other Class of Drugs
Segmentation by Treatment Type
Segmentation by Gender Type
Segmentation by Geography
North America – US
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan
Within the global graft versus host disease (GVHD) treatment market, corticosteroid drugs are projected to hold a significant share. However, the fastest-growing segment during the forecast period is expected to be kinase inhibitors. Physicians commonly recommend corticosteroids as a front-line therapy due to their established safety and efficacy, especially when compared to alternative drugs with lesser proven safety and efficacy. This preference for corticosteroids in front-line therapy further reinforces their prominent role in the market.
In terms of GVHD subtypes, acute GVHD (aGVHD) is anticipated to contribute significantly to the global market. Research conducted by the National Center of Biotechnology Information in 2020 suggests that around 30% to 50% of individuals who undergo hematopoietic stem cell transplantation develop acute GVHD.
Considering gender types, males are expected to dominate the market, although females are projected to be the fastest-growing segment during the forecast period. The rise in hematopoietic stem cell transplantations among males is a key factor contributing to the growth of this segment.
Geographically, the United States currently holds a dominant position in the graft versus host disease treatment market. However, China is expected to exhibit faster growth with a high compound annual growth rate (CAGR). The growth factors driving the United States market include the increasing incidence and prevalence of GVHD patients, the presence of key players, and improved accessibility to healthcare due to a well-established healthcare infrastructure and widespread availability of novel therapeutics.
The market for GVHD treatment is currently characterized by the presence of numerous companies offering generic and off-label drugs, as well as select pharmaceutical and biotechnology companies providing patented and commercially available drugs specifically designed for GVHD treatment. Notable players in this market segment include Kadmon, Incyte Corp, Pharmacyclics, Bristol Myers Squibb, and Mesoblast.
Given the ongoing development of over 135 molecules at various stages, it is anticipated that new vendors will enter the market with innovative mechanisms of action and improved safety and efficacy profiles compared to existing patented commercial drugs used for treating GVHD. This influx of new vendors is likely to contribute to the expansion and evolution of the GVHD treatment market.
Key companies profiled in this report include Incyte, Pharmacyclics, Bristol-Myers Squibb, JCR Pharmaceuticals Co., Ltd., Takeda Pharmaceutical Co Ltd (Takeda), MaaT Pharma, XeniKos, Medac GmbH, Mesoblast, Kadmon, Jazz Pharmaceuticals, Gsk, Novartis, Syndax Pharmaceuticals Inc, Neovii, ElsaLys Biotech, Mallinckrodt, Regimmune, Roche, Altrubio, CTTQ, Equillium, Janssen (Johnson & Johnson), ASC Therapeutics, MSD, Genentech, Sun Pharma, Mink Therapeutics, Pluristem.
Key Questions Answered
WHAT IS THE PROJECTED SIZE OF THE GRAFT VERSUS HOST DISEASE (GVHD) MARKET BY 2027?
The graft versus host disease market is expected to reach a value of USD 990.16 million by 2027, with a compound annual growth rate (CAGR) of 7.44% during the period of 2021-2027.
WHAT OPPORTUNITIES ARE AVAILABLE FOR VENDORS IN THE GRAFT VERSUS HOST DISEASE MARKET?
Vendors in the graft versus host disease market have the opportunity to benefit from significant investments in research and development capabilities and infrastructure, both from the industry and government sectors. These investments are expected to create lucrative opportunities for vendors in the market.
WHO ARE THE KEY PLAYERS IN THE GRAFT VERSUS HOST DISEASE TREATMENT MARKET?
The key players in the graft versus host disease treatment market include Incyte, Pharmacyclics, Bristol-Myers Squibb, JCR Pharmaceuticals Co., Ltd., Takeda Pharmaceutical Co Ltd (Takeda), and MaaT Pharma. These companies play a significant role in the development and provision of treatments for graft versus host disease.
WHAT ARE THE FUTURE PROJECTIONS FOR THE TREATMENT OF THE GRAFT VERSUS HOST DISEASE MARKET?
In the coming years, advancements in the field of graft versus host disease treatment are expected to introduce new monoclonal antibodies and inhibitors targeting critical costimulatory molecules. These therapeutic strategies aim to enhance the prevention and treatment of patients suffering from acute graft versus host disease.